Why Twist Bioscience Corporation (TWST) Stock Rose 8.7% on Sep 17, 2026
The clearest new catalyst: Eli Lilly TuneLab partnership (announced Sep 16).
Why did TWST stock rise?
Twist Bioscience rose 8.73% to $155.56 on Thursday, September 17, 2026 (intraday high $165.70), extending a multi-day rally. The move built on the prior day's news that Twist had joined Eli Lilly's TuneLab AI drug-discovery platform as an antibody-characterization data-services provider, and on a fresh September 17 Leerink price-target raise to $160 from $120 (Outperform). The run had actually begun before the Lilly deal, so it reflected broad AI-drug-discovery enthusiasm, not a single event.
- Eli Lilly TuneLab partnership (announced Sep 16): On Wednesday, September 16, Twist announced it had joined Lilly TuneLab as a provider of antibody-characterization data services, including data supporting Lilly's AbLab antibody-developability model; TuneLab participants can order Twist antibody services using TuneLab-preferred protocols, producing wet-lab data used by the AI/ML platform. The deal lifted TWST about 3.6% on September 16, and September 17's advance was described as building on it.
- Fresh Leerink price-target increase (Sep 17): On September 17, Leerink's Puneet Souda raised the price target to $160 from $120, keeping an Outperform rating, citing increased conviction in the AI-drug-discovery opportunity and Twist's long-term growth assumptions — the genuinely same-day analyst catalyst.
- A multi-day AI-enthusiasm rally: The gain extended a multi-day run — TWST rose 5.92% on September 14, 2.49% on September 15 and 3.60% on September 16 — so the rally started before the Lilly announcement and reflected broad enthusiasm for Twist's role in AI-driven drug discovery, not one catalyst. The stock reached a multi-year high (intraday $165.70).
How the story developed
- September 14-15, 2026TWST rallies (+5.92% then +2.49%) on AI-drug-discovery enthusiasm, before the Lilly news.
- September 16, 2026Twist announces it has joined Eli Lilly's TuneLab as an antibody-characterization data-services provider; shares rise ~3.6%.
- September 17, 2026Leerink raises its target to $160 from $120 (Outperform); TWST closes up 8.73% at $155.56 (intraday high $165.70), a multi-year high.
What it could mean for TWST investors
The constructive case
- The Lilly TuneLab tie-up is concrete validation of Twist's role in AI-driven antibody/drug discovery, a large potential demand driver.
- Fresh sell-side support (Leerink's $160 target) reflects rising conviction in Twist's long-term growth story.
The cautious case & what could invalidate it
- After a sharp multi-day run to multi-year highs, expectations are elevated and the valuation is stretched.
- Potential equity dilution is a recurring overhang for Twist.
- Part of the enthusiasm is thematic (AI drug discovery), so the stock is sensitive to any cooling in that narrative.
Initial detection
BestStocks first flagged TWST intraday on Sep 17, 2026; this analysis was finalized after the close using the confirmed +8.7% session move and additional catalyst research.
Show the initial intraday note
Twist Bioscience Corporation (TWST) rose 8.73% to close at $155.56 on Thursday, September 17, 2026 (an intraday high of $165.70), extending a multi-day rally to a multi-year high. Two catalysts fueled it: the prior day's announcement that Twist had joined Eli Lilly's TuneLab AI drug-discovery platform as a provider of antibody-characterization data services, and a fresh September 17 Leerink price-target increase to $160 from $120 (Outperform) citing conviction in the AI-drug-discovery opportunity.
What to watch next: The bull thesis rests on AI-driven demand for Twist's synthetic DNA and antibody services (the Lilly TuneLab tie-up is the marquee example), so watch for additional pharma/AI partnerships, order trends and margin progress. After a sharp multi-day run to multi-year highs, the stock is priced for that momentum to continue, and potential equity dilution is a recurring concern for the name.
Frequently asked questions
Why did Twist Bioscience Corporation (TWST) stock rise on Sep 17, 2026?
Twist Bioscience rose 8.73% to $155.56 on Thursday, September 17, 2026 (intraday high $165.70), extending a multi-day rally. The move built on the prior day's news that Twist had joined Eli Lilly's TuneLab AI drug-discovery platform as an antibody-characterization data-services provider, and on a fresh September 17 Leerink price-target raise to $160 from $120 (Outperform). The run had actually begun before the Lilly deal, so it reflected broad AI-drug-discovery enthusiasm, not a single event.
How much did TWST stock rise on Sep 17, 2026?
TWST rose 8.7% during the Sep 17, 2026 trading session.
What were the main drivers behind TWST's move?
Eli Lilly TuneLab partnership (announced Sep 16); Fresh Leerink price-target increase (Sep 17); A multi-day AI-enthusiasm rally.